** Shares of Tandem Diabetes Care up 2.81% at $45.29 after rival Insulet Corp raises FY rev growth forecast
** Insulet raises its annual revenue growth forecast, banking on strong sales of its wearable, tubeless insulin pumps
** PODD now sees FY rev growth of 14%-18% vs. 12%-17% growth expected earlier and above analysts' average estimates of 15.62%, according to LSEG data
** Earlier in May TNDM had also raised its FY adj sales forecast to $868 mln from $850 mln
** TNDM up about 52.65% YTD
(Reporting by Vaibhav Sadhamta)
((Vaibhav.Sadhamta@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments